%0 Journal Article
%T Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
%A Andr¨¦ Poisl Fay
%A Gustavo Werutsky
%A Tom¨¢s Reinert
%J SCIE-indexed Journal
%D 2018
%R 10.21037/21115
%X The ALTERNATIVE trial has shown progression-free survival (PFS) benefit with the addition of lapatinib (LAP) to trastuzumab (TRAS) and an aromatase inhibitor (AI) among postmenopausal patients with hormone receptor (HR), human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC). These findings were reported by Johnston et al. in the Journal of Clinical Oncology (1)
%U http://tcr.amegroups.com/article/view/21115/html